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Abstract
Background: Although the effectiveness of perioperative adjuvant therapy in the treatment of hepatocellular
carcinoma (HCC) has been investigated, the efficacy of preoperative therapy is unclear. Herein, we report a case of
pathological complete response after percutaneous isolated hepatic perfusion (PIHP) for HCC involving portal vein
tumor thrombosis (PVTT).
Case presentation: A 77-year-old woman was referred to our institute with a liver mass detected on a routine
health screening. Computed tomography revealed a 28 × 25 mm HCC in the left lobe of the liver and a tumor
thrombus in the left and right portal branches (T4N0M0, stage IVA). The patient received a single dose of
preoperative PIHP with doxorubicin plus mitomycin C, without severe toxicity. After the chemotherapy, she
underwent extended left hepatic lobectomy and thrombectomy of the PVTT. No cancer cells were detected during
histopathological analysis, indicating pathological complete response. She remained relapse-free 12 months after
the surgery.
Conclusions: We experienced a case of pathological complete response after preoperative PIHP with doxorubicin
plus mitomycin C for HCC involving PVTT.
Keywords: Hepatocellular carcinoma, Portal vein tumor thrombosis, Percutaneous isolated hepatic perfusion,
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and third leading cause of cancer-related
deaths worldwide [1]. Surgical resection is the most
promising treatment for long-term survival although
only 10–37 % of the cases with HCC are eligible for sur-
gical resection because of the extent of disease or
cirrhosis-related liver dysfunction [2]. Portal vein tumor
thrombosis (PVTT) is a common complication of HCC
associated with a poor prognosis [3]. For the treatment
of HCC involving PVTT, according to Japanese Clinical
Practice Guidelines for Hepatocellular Carcinoma 2013,
liver resection may be selected for patients with liver dam-
age of grade A along with three or less HCC [4]. However,
the use of curative surgical resection is controversial be-
cause it is associated with a high recurrence rate [5–9].
Therefore, effective multimodality treatment approaches
should be explored to improve the overall and survival
outcomes. Percutaneous isolated hepatic perfusion (PIHP)
is a form of high-dose regional chemotherapy that enables
the administration of cytotoxic agents at a dose of up to
10 times the maximally tolerated dose, while reducing ex-
posure of the entire body to the major adverse effects of
the therapeutic agents [10]. We showed in our previous
studies that PIHP is safe and effective in the treatment of
local tumors, even in patients with macroscopic PVTT
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[11, 12]. In order to avoid further tumor cell dissemination
and reduce the stage of the tumor before surgery, we
tested the efficacy of administering PIHP before surgery.
Herein, we report a case of HCC involving PVTT for
which a pathological complete response was achieved by
the administration of PIHP with doxorubicin plus mito-
mycin C before surgery.
Case presentation
A 77-year-old woman who was diagnosed with chronic
hepatitis C at the age of 50 years was referred to a local
hospital for follow-up. Abdominal ultrasonography
showed a tumor in the left lobe of the liver. She was re-
ferred to our department for further examination and
treatment. Laboratory data were as follows: platelet count
126 K/uL, total bilirubin 0.8 mg/dL, aspartate aminotrans-
ferase (AST) 176 U/L, alanine aminotransferase (ALT)
157 U/L, albumin 4.2 g/dL, prothrombin time 90.6 %, in-
docyanine green 15-min retention test (ICG R15) 19.7 %,
α-fetoprotein (AFP) 16 ng/mL, protein induced by vitamin
K absence or antagonist II (PIVKA-II) 2873 mAU/mL,
hepatitis C virus (HCV) Ab positive, HCV RNA 6.54
logIU/mL. The liver damage was grade A and Child-Pugh
classification was class A. Contrast-enhanced computed
tomography (CT) showed a 28 × 25 mm tumor in seg-
ment 4, with a tumor thrombus in the left portal branch
reaching the right portal branch, both of which were en-
hanced in the arterial phase and washed out in the equi-
librium phase (Fig. 1). The patient was diagnosed with
clinical stage T4 (Vp4) bN0M0, stage IVA HCC involving
PVTT, according to the tumor-node-metastasis classifica-
tion of the Liver Cancer Study Group in Japan (6th edi-
tion) [13], which indicated poor prognosis when treated
with surgery only. After providing informed consent, the
patient decided to receive PIHP before surgery. She re-
ceived continuous hepatic arterial infusion (HAI) of
100 mg/m2 doxorubicin plus 30 mg/m2 mitomycin C for
30 min (Fig. 2). She recovered from a single dose of PIHP
without severe toxicity, except a reduction in the grade 4
neutrophil counts (neutrophil count 200/μL) that was
treated with recombinant G-CSF (CTCAE version 4.0)
[14] on the 12th day after PIHP. The serum level of AST
and ALT rose up to 516 U/L and 242 U/L on the 4th day
after PIHP, respectively. CT showed reduction of tumor
volume and no enhancement of the PVTT after PIHP
(Fig. 3). The efficacy of chemotherapy was determined to
be treatment efficacy (TE) 3 according to the criteria of
the Liver Cancer Study Group in Japan (6th edition) [13]
and based on the partial response achieved. The clinical
stage after PIHP was determined to be T4N0M0, stage
IVA. The serum levels of AFP and PIVKA-II dramatically
declined to 16 ng/mL and 21 mAU/mL, respectively
(Fig. 4). Subsequently, the neutrophil increased to 2400/
μL, and the serum levels of AST/ALT improved to 36/
61 U/L. The patient underwent extended left hepatic lob-
ectomy and PVTT thrombectomy 6 weeks after PIHP.
The operative findings revealed the extent of PVTT to be
from the left and right portal branches to the portal trunk.
Because the PVTT did not adhere to the portal vein wall,
which would have led to a combined resection, she
Fig. 1 Contrast-enhanced CT before preoperative PIHP: CT showing a 28 × 25 mm HCC in segment 4 (a) and PVTT (yellow circle) in the left portal
branch reaching the right portal (b). PVTT was enhanced in the arterial phase (c) and washed out in the equilibrium phase (d)
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underwent thrombectomy with the back flow perfusion
method and closure of the stump through a running su-
ture of the portal vein with radical intent.
Histological examination of the resected specimen re-
vealed complete necrosis without any viable cancer cells
in the primary tumor and PVTT (Fig. 5) and we further
showed that treatment efficacy 4 and pathological
complete response were achieved. The patient recovered
uneventfully after surgery and remained relapse-free
12 months after the surgery, without any postoperative
chemotherapy.
Discussion
The optimal treatment method for patients with HCC in-
volving PVTT in the portal bifurcation or the main trunk
remains controversial [15]. PVTT represents one of the
most important prognostic factors in patients with HCC.
Most patients with HCC involving extensive PVTT have
multiple intrahepatic metastases at the time of diagnosis
and they are considered poor surgical candidates. If left
untreated, patients with HCC involving PVTT have a me-
dian overall survival (OS) of 2–4 months [16, 17]. PVTT
is also a causative factor for intrahepatic tumor dissemin-
ation, which primarily accounts for the poor prognosis in
this group of patients [18, 19]. The most common staging
system for HCC employed in American and European
centers, the Barcelona Clinic Liver Cancer (BCLC) system,
recommends against surgical resection in cases involving
PVTT [20]. In a previous series of patients who under-
went hepatectomy and thrombectomy for HCC involving
PVTT in the main portal trunk, the 1- and 3-year OS
rates were 25 and 4 %, respectively, and the disease-free
survival rates were 3 % and 0 %, respectively [21]. How-
ever, surgical resection is considered the only curative
Fig. 2 System of PIHP: The specially designed 4-lumen/2-balloon catheter was introduced into the retrohepatic inferior vena cava through the femoral
vein. The hepatic effluent was isolated by balloon inflation and pumped to charcoal filters via the fenestrations of one major catheter lumen. The filtered
blood was returned straight to the right atrium through the other major lumen with an opening at the distal tip of the catheter. The patient received a
30-min continuous HAI of 100 mg/m2 doxorubicin plus 30 mg/m2 mitomycin C. At the end of HAI, extracorporeal drug filtration was maintained at least
for 10 min, and the 4-lumen/2-balloon catheter was removed
Fig. 3 Contrast-enhanced CT after preoperative PIHP: CT showing the reduction of the main tumor volume (a) and no enhancement of the PVTT
(yellow circle) after PIHP (b, c)
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option. To improve the efficacy of surgical resection for
HCC involving PVTT, neoadjuvant/adjuvant therapies
were evaluated in several studies [6, 22–24]. Because of
the heterogeneous results, the effect of neoadjuvant ther-
apy on the OS was inconclusive.
Since 1989, our center has been using PIHP for the
treatment of advanced multiple HCC [6]. In our previ-
ous study, the data suggested a significant tumoricidal
impact on less sensitive HCC and sufficient sorption
with charcoal hemoperfusion of high-dose doxorubicin
and MMC regimen [10]. In 2003, we reported the effi-
cacy of reductive surgery plus PIHP for multiple HCC,
including HCC with macroscopic PVTT [11]. The
favorable survival profile suggested the efficacy of the
second PIHP in local tumor control. Based on these
previous reports, we extended the use of PIHP as pre-
operative therapy. In the present case, because the
PVTT in the left portal branch reached the right portal
branch and the high level of PIVKA-II indicated high
recurrence possibility, surgery was planned after
preoperative chemotherapy with PIHP. To the best of
our knowledge, this is the first report of a case with
pathological complete response after preoperative
chemotherapy with PIHP in advanced HCC involving
PVTT. Although there were several reports of spontan-
eous regression of PVTT [25, 26], in the present case,
we judged PIHP was effective based on the pathohisto-
logical assessment.
Recently, the efficacy of preoperative HAI chemother-
apy has been shown in patients with HCC and PVTT
[27, 28]. Because PIHP has shown a high objective
response rate (70.6 % complete and partial response)
and safety, it might be a better alternative instead of pre-
operative therapy.
Fig. 4 Perioperative clinical course: After preoperative PIHP, the serum level of AFP and PIVKA-II dramatically declined. She recovered uneventfully
after the surgery and remained relapse-free 12 months after the surgery without any postoperative chemotherapy
Fig. 5 Macroscopic (a) and microscopic (b) findings on the resected specimen after PIHP: No residual tumor was found at the original site of the
HCC, which extended into the portal branch in the left lobe of the liver. Instead, it was completely replaced by granulated and fibrous tissue.
Microscopic findings in non-cancerous lesion showed grade 1 inflammation and stage 4/4 fibrosis with histopathologic features of chronic HCV.
(hematoxylin and eosin stain, ×20)
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The clinical question of whether preoperative or postop-
erative PIHP is better should be addressed. Preoperative
PIHP might not only reduce post-curative therapy recur-
rence but also downstage tumors from an unresectable to
a resectable stage.
Conclusions
In conclusion, further investigation into surgery following
neoadjuvant chemotherapy as a possible therapeutic
option for HCC involving PVTT is warranted. PIHP with
doxorubicin plus mitomycin C is a feasible and promising
preoperative chemotherapy for HCC involving PVTT.
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